Homepage>Company>Media>Pharma News>2017>Lenvatinib Significantly Improved Overall Survival in Older Patients with Locally Recurrent or Metastatic, Progressive, Radioactive Iodine-Refractory Differentiated Thyroid Cancer
Lenvatinib Significantly Improved Overall Survival in Older Patients with Locally Recurrent or Metastatic, Progressive, Radioactive Iodine-Refractory Differentiated Thyroid Cancer